Nanomolar small molecule inhibitors for αvβ6, αvβ5, and αvβ3 integrins

被引:167
作者
Goodman, SL
Hölzemann, G
Sulyok, GAG
Kessler, H
机构
[1] Merck KGaA, Dept Preclin Oncol, D-64271 Darmstadt, Germany
[2] Merck KGaA, Dept Med Chem, D-64271 Darmstadt, Germany
[3] Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany
关键词
D O I
10.1021/jm0102598
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Integrin adhesion receptors frequently recognize a core amino acid sequence, Arg-Gly-Asp, in their target ligands. Inhibitors with the ability to inhibit one or a small subset of such RGD-dependent integrins have been invaluable in defining their biological function. Here, we have characterized low molecular weight inhibitors for their ability to specifically inhibit alphavbeta6 integrin, a fibronectin/tenascin receptor. As of yet, no nonpeptidic inhibitor of alphavbeta6 was known. New peptidomimetic and nonpeptidic compounds were examined in isolated integrin binding assays and in cell adhesion assays for their ability to block alphavbeta6, alphavbeta3, alphavbeta5, and alpha1Ibbeta3 integrins. The compounds are based on an aromatically substituted beta amino acid or glutaric acid derivative as an acidic center and an aminopyridyl or guanidyl residue as a basic mimetic. We found several classes of inhibitors with different selectivities, especially mono- or biselectivity on the alphav-integrins alphavbeta6 and alphavbeta3, and nanomolar activity. Furthermore, nearly all compounds are inactive on alphaIIbbeta3. Compound 11 is the first specific, peptidomimetic inhibitor of the alphavbeta6 integrin receptor.
引用
收藏
页码:1045 / 1051
页数:7
相关论文
共 57 条
  • [11] Carron CP, 1998, CANCER RES, V58, P1930
  • [12] INHIBITION OF NEOINTIMAL HYPERPLASIA BY BLOCKING ALPHA(V)BETA(3), INTEGRIN WITH A SMALL PEPTIDE ANTAGONIST GPENGRGDSPCA
    CHOI, ET
    ENGEL, L
    CALLOW, AD
    SUN, SP
    TRACHTENBERG, J
    SANTORO, S
    RYAN, US
    [J]. JOURNAL OF VASCULAR SURGERY, 1994, 19 (01) : 125 - 134
  • [13] Clark RAF, 1996, BRIT J DERMATOL, V135, P46
  • [14] A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin α5β1-fibronectin-M1 protein complexes
    Cue, D
    Southern, SO
    Southern, PJ
    Prabhakar, J
    Lorelli, W
    Smallheer, JM
    Mousa, SA
    Cleary, PP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) : 2858 - 2863
  • [15] N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists
    Dechantsreiter, MA
    Planker, E
    Mathä, B
    Lohof, E
    Hölzemann, G
    Jonczyk, A
    Goodman, SL
    Kessler, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) : 3033 - 3040
  • [16] DECHANTSREITER MA, 1998, PEPTIDES 1996, P329
  • [17] NONPEPTIDE FIBRINOGEN RECEPTOR ANTAGONISTS .2. OPTIMIZATION OF A TYROSINE TEMPLATE AS A MIMIC FOR ARG-GLY-ASP
    EGBERTSON, MS
    CHANG, CTC
    DUGGAN, ME
    GOULD, RJ
    HALCZENKO, W
    HARTMAN, GD
    LASWELL, WL
    LYNCH, JJ
    LYNCH, RJ
    MANNO, PD
    NAYLOR, AM
    PRUGH, JD
    RAMJIT, DR
    SITKO, GR
    SMITH, RS
    TURCHI, LM
    ZHANG, GX
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (16) : 2537 - 2551
  • [18] REQUIREMENT OF THE NPXY MOTIF IN THE INTEGRIN BETA-3 SUBUNIT CYTOPLASMIC TAIL FOR MELANOMA CELL-MIGRATION IN-VITRO AND IN-VIVO
    FILARDO, EJ
    BROOKS, PC
    DEMING, SL
    DAMSKY, C
    CHERESH, DA
    [J]. JOURNAL OF CELL BIOLOGY, 1995, 130 (02) : 441 - 450
  • [19] DEFINITION OF 2 ANGIOGENIC PATHWAYS BY DISTINCT ALPHA(V) INTEGRINS
    FRIEDLANDER, M
    BROOKS, PC
    SHAFFER, RW
    KINCAID, CM
    VARNER, JA
    CHERESH, DA
    [J]. SCIENCE, 1995, 270 (5241) : 1500 - 1502
  • [20] Gibson C, 2001, ANGEW CHEM INT EDIT, V40, P165, DOI 10.1002/1521-3773(20010105)40:1<165::AID-ANIE165>3.0.CO